Merck’s Gardasil 9 Receives the US FDA’s Approval to Prevent HPV-Related Head and Neck Cancers
Merck’s KEYTRUDA (pembrolizumab) Receives CHMP Recommendation for 1L Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)
Shots:
- The US FDA has approved an expanded indication for Gardasil 9 for the prevention of oropharyngeal and other head and neck cancers caused by HPV Types 16, 18, 31, 33, 45, 52, and 58
- The FDA has approved the therapy under accelerated approval based on effectiveness in preventing HPV-related anogenital disease. The continued approval for the indication may be contingent upon verification and description of clinical benefit in a confirmatory trial while the trial is undergoing
- Gardasil 9 is (human papillomavirus 9-valent vaccine, recombinant) is now approved for the prevention of HPV-related cervical, vaginal, vulvar, anal, oropharyngeal, and other head and neck cancers for females and males aged 9-45yrs.
Click here to read full press release/ article | Ref: Merck | Image: Merck
Related News: Merck’s Gardasil 9 Receives FDA’s Expanded Label Approval for Prevention of HPV Related Disorders